Dosage and formulation issues: oral vitamin E therapy in children

Tone Westergren, Betty Kalikstad, Tone Westergren, Betty Kalikstad

Abstract

Purpose: Oral vitamin E is used in several childhood diseases, but dosage recommendations differ. Few oral products have a marketing authorization for therapeutic use in children. Preliminary data indicate differences in bioavailability among the various vitamin E compounds. Our objective was to review published data on oral vitamin E therapy in neonates and children in order to establish dosage recommendations at a local level.

Methods: A literature search was conducted, including Medline Ovid, EMBASE (1980-Feb 2008), Cochrane databases, product monographs, handbooks, and textbooks.

Results: The main vitamin E compounds being used in children are alpha-tocopherol, alpha-tocopheryl acetate, and tocofersolan. The most data are available on tocopheryl acetate, both in neonates and older children. In children with malabsorption disorders, tocofersolan appears to have an increased bioavailability compared to tocopherol or tocopheryl acetate. Published data on pharmacokinetics and dosages for clinical use are few and heterogeneous. No pharmacokinetic studies were found for tocofersolan in neonates and infants. There are few comparative studies on pharmacokinetics, therapeutic use, and adverse drug reactions (ADRs) in children. Dosages used in clinical studies and dosage recommendations in handbooks differ considerably.

Conclusions: The differences in dosing recommendations in children may be due to lack of systematic studies. Existing published data on oral vitamin E do not provide a basis for evaluation of dosage recommendations in children. Comparative clinical studies are required for scientific evaluation of pharmacokinetics, dosage regimens, and efficacy/ADR assessments in children.

References

    1. Brion LP, Bell EF, Raghuveer TS (2003) Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 4:CD003665. doi:10.1002/14651858.CD003665
    1. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. Br Med J. 2000;320:79–82. doi: 10.1136/bmj.320.7227.79.
    1. Brion F, Nunn AJ, Rieutord A. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003;92:486–490.
    1. Conroy S. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr. 2003;92:408–410.
    1. Westergren T, Kalikstad B. Liquid vitamin E for children: treatment with a blindfold? Tidsskr Nor Laegeforen. 2006;126:902–904.
    1. Eitenmiller R, Lee J (2004) Vitamin E: chemistry and biochemistry. In: Vitamin E Food chemistry, composition and analysis. Marcel Dekker, New York, pp 2–5
    1. Roxborough HE, Burton GW, Kelly FJ. Inter- and intra-individual variation in plasma and red blood cell vitamin E after supplementation. Free Radic Res. 2000;33:437–445. doi: 10.1080/10715760000300971.
    1. Eastman (2008) Eastman vitamin E TPGS, food grade. Accessed May 20, 2008
    1. Jeanes YM, Hall WL, Ellard S, et al. The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix. Br J Nutr. 2004;92:575–579. doi: 10.1079/BJN20041249.
    1. Jansson L, Lindroth M, Työppönen J. Intestinal absorption of vitamin E in low birth weight infants. Acta Paediatr Scand. 1984;73:329–332. doi: 10.1111/j.1651-2227.1994.tb17743.x.
    1. Taketomo CK, Hodding JH, Kraus DM (2007) Pediatric dosage handbook, 14th ed. Lexi-Comp, Hudson, OH, pp 1620–1622
    1. Brigelius-Flohé R, Kelly FJ, Salonen JT, et al. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002;76:703–716.
    1. BMJ Publishing Group (2007) BNF for children. London, p 549
    1. RCPCH Publications (2003) Medicines for children. London, pp 670–671
    1. Bhatt D, Reber DJ, Wirtschafter DD et al (1997) Neonatal drug formulary. Fontana, CA, pp 432–433
    1. Young TE, Mangum B (2008) NeoFax. Thomson Reuters, Montvale, NJ, p 286
    1. Hittner HM, Godio LB, Rudolph AJ, et al. Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med. 1981;305:1365–1371.
    1. Fischer AF, Inguillo D, Martin DM, et al. Carboxyhemoglobin concentration as an index of bilirubin production in neonates with birth weight less than 1,500 grams: a randomized double-blind comparison of supplemental oral vitamin E and placebo. J Pediatr Gastroenterol Nutr. 1987;6:748–751.
    1. Smith DW, Cohen RS, Vreman HJ, et al. Bilirubin production after supplemental oral vitamin E therapy in preterm infants. J Pediatr Gastroenterol Nutr. 1985;4:38–44.
    1. Friedman CA, Wender DF, Temple DM, et al. Serum alpha-tocopherol concentrations in preterm infants receiving less than 25 mg/kg/day alpha-tocopherol acetate supplements. Dev Pharmacol Ther. 1988;11:273–280.
    1. Neal PR, Erickson P, Baenziger JC, et al. Serum vitamin E levels in the very low birth weight infant during oral supplementation. Pediatrics. 1986;77:636–640.
    1. Issa S, Rotthauwe HW, Burmeister W. 25 hydroxyvitamin D and vitamin E absorption in healthy children and children with chronic intrahepatic cholestasis. Eur J Pediatr. 1989;148:605–609. doi: 10.1007/BF00441510.
    1. Guggenheim MA, Ringel SP, Silverman A, et al. Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: diagnosis and treatment with alpha tocopherol. J Pediatr. 1982;100:51–58. doi: 10.1016/S0022-3476(82)80234-5.
    1. Sokol RJ, Heubi JE, Butler-Simon N, et al. Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-α-tocopheryl polyethylene glycol-1000 succinate. Gastroenterology. 1987;93:975–985.
    1. Feranchak AP, Sontag MK, Wagener JS, et al. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. J Pediatr. 1999;135:601–610. doi: 10.1016/S0022-3476(99)70059-4.
    1. Winklhofer-Roob BM, van’t Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-α-tocopherol compared with all-rac-α-tocopheryl acetate preparations. Am J Clin Nutr. 1996;63:722–728.
    1. Wilfond BS, Farrell PM, Laxova A, et al. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Clin Pediatr (Phila) 1994;33:2–7. doi: 10.1177/000992289403300101.
    1. Moyano D, Vilaseca MA, Pineda M, et al. Tocopherol in inborn errors of intermediary metabolism. Clin Chim Acta. 1997;263:147–155. doi: 10.1016/S0009-8981(97)00061-2.
    1. Shirakata Y, Shiraishi S, Sayama K, et al. High-dose tocopherol acetate therapy in epidermolysis bullosa siblings of the Cockayne-Touraine type. J Dermatol. 1993;20:723–725.
    1. Eldamhoughy S, Elhelw Z, Yamamah G, et al. The vitamin E status among glucose-6 phosphate dehydrogenase deficient patients and effectiveness of oral vitamin E. Int J Vitam Nutr Res. 1988;58:184–188.
    1. Tahzib M, Frank R, Gauthier B, et al. Vitamin E treatment of focal segmental glomerulosclerosis: results of an open-label study. Pediatr Nephrol. 1999;13:649–652. doi: 10.1007/s004670050674.
    1. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000;136:734–738. doi: 10.1067/mpd.2000.106566.
    1. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48–55. doi: 10.1097/00005176-200401000-00012.
    1. Nobili V, Manco M, Devito R, et al. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1553–1561. doi: 10.1111/j.1365-2036.2006.03161.x.
    1. Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16:1812–1817. doi: 10.1023/A:1018939006780.
    1. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol) J Control Release. 2003;86:33–48. doi: 10.1016/S0168-3659(02)00320-6.
    1. Prasad YVR, Puthli SP, Eaimtrakarn S, et al. Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats. Int J Pharm. 2003;250:181–190. doi: 10.1016/S0378-5173(02)00544-6.
    1. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1996;59:297–303. doi: 10.1016/S0009-9236(96)80007-5.
    1. Sokol RJ, Johnson KE, Karrer FM, et al. Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet. 1991;338:212–214. doi: 10.1016/0140-6736(91)90349-T.
    1. Holt DW, Johnston A. Cyclosporine and vitamin E. Lancet. 1991;338:697. doi: 10.1016/0140-6736(91)91275-Y.
    1. Helsing E. Vitamins. In: Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 14. Amsterdam: Elsevier; 2000. pp. 1354–1356.
    1. Liede KE, Haukka JK, Saxen LM, et al. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Ann Med. 1998;30:542–546. doi: 10.3109/07853899809002602.
    1. Higashi A, Ikeda T, Matsukura M, et al. Serum zinc and vitamin E concentrations in handicapped children treated with anticonvulsants. Dev Pharm Ther. 1982;5(3–4):109–113.
    1. Gold Standard (2009) Vitamin E. . Accessed May 28, 2009
    1. Dimitrov NV, Meyer-Leece C, McMillan J, et al. Plasma α-tocopherol concentrations after supplementation with water- and fat-soluble vitamin E. Am J Clin Nutr. 1996;64:329–335.
    1. Balistreri WF, Farrell MK, Bove KE. Lessons from the E-Ferol tragedy. Pediatrics. 1986;78:503–506.
    1. Mino M. Use and safety of elevated dosages of vitamin E in infants and children. Int J Vitam Nutr Res. 1989;30:69–80.
    1. Inoue N. Iatrogenic alcohol in medication. Clin Pediatr (Phila) 2004;43:399–400. doi: 10.1177/000992280404300414.
    1. Ferlin MLS, Chuan LS, Jorge SM, et al. Early anemia of prematurity. Nutr Res. 1998;18:1161–1173. doi: 10.1016/S0271-5317(98)00097-9.
    1. Jansson L, Holmberg L, Nilsson B, et al. Vitamin E requirements of preterm infants. Acta Paediatr Scand. 1978;67:659–663. doi: 10.1111/j.1651-2227.1978.tb16354.x.
    1. Melhorn DK, Gross S, Childers G. Vitamin E-dependent anemia in the premature infant. I. Effects of large doses of medicinal iron. J Pediatr. 1971;79:569–580. doi: 10.1016/S0022-3476(71)80302-5.
    1. Pathak A, Roth P, Piscitelli J, et al. Role of vitamin E supplementation during erythropoietin treatment of the anemia of prematurity. Arch Dis Child Fetal Neonatal Ed. 2003;88:F324–F328. doi: 10.1136/fn.88.4.F324.
    1. Zipursky A, Brown EJ, Watts J, et al. Oral vitamin E supplementation for the prevention of anemia in premature infants: a controlled trial. Pediatrics. 1987;79:61–68.
    1. Chowers I, Banin E, Merin S, et al. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye. 2001;15:525–530.
    1. Clark JH, Nagamori KE, Ellett ML, et al. Vitamin E sufficiency in children with cholestasis: a comparison between erythrocyte peroxide hemolysis and serum α-tocopherol. Clin Chim Acta. 1985;153:117–124. doi: 10.1016/0009-8981(85)90162-7.
    1. Guggenheim MA, Ringel SP, Silverman A, et al. Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: clinical and muscle biopsy findings and treatment with α-tocopherol. Ann N Y Acad Sci. 1982;393:84–93. doi: 10.1111/j.1749-6632.1982.tb31235.x.
    1. Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. Can Med Assoc J. 1985;132:41–44.
    1. Lubrano R, Frediani T, Citti G, et al. Erythrocyte membrane lipid peroxidation before and after vitamin E supplementation in children with cholestasis. J Pediatr. 1989;115:380–384. doi: 10.1016/S0022-3476(89)80835-2.
    1. Muller DPR, Lloyd JK, Wolff OH. The role of vitamin E in the treatment of the neurological features of abetalipoproteinaemia and other disorders of fat absorption. J Inherit Metab Dis. 1985;8(Suppl.1):88–92. doi: 10.1007/BF01800666.
    1. Nakagawa M, Tazawa Y, Kobayashi Y, et al. Familial intrahepatic cholestasis associated with progressive neuromuscular disease and vitamin E deficiency. J Pediatr Gastroenterol Nutr. 1984;3:385–389.
    1. Roma E, Klontza D, Kairis M, et al. Familial hypobetalipoproteinaemia. Helv Paediatr Acta. 1984;39:145–151.
    1. Roongpraiwan R, Suthutvoravut U, Feungpean B, et al. Effect of oral vitamin E supplementation in children with cholestasis. J Med Assoc Thai. 2002;8(Suppl 4):1199–1204.
    1. Socha P, Koletzko B, Pawlowska J, et al. Treatment of cholestatic children with water-soluble vitamin E (alpha-tocopheryl polyetylene glycol succinate): effects on serum vitamin E, lipid peroxides and polyunsaturated fatty acids. J Pediatr Gastroenterol Nutr. 1997;24:189–193. doi: 10.1097/00005176-199702000-00013.
    1. Sokol RJ, Guggenheim M, Iannacone S, et al. Improved neurologic function after long-term correction of vitamin E deficiency in children with chronic cholestasis. N Engl J Med. 1985;313:1580–1586.
    1. Sokol RJ, Butler-Simon N, Conner C, et al. Multicenter trial of d-α-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology. 1993;104:1727–1735.
    1. Traber MG, Kayden HJ, Balmer Green J, et al. Absorption of water miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am J Clin Nutr. 1986;44:914–923.
    1. European Medicines Agency (EMEA) (2009) Vedrop. European Public Assessment Report, 29. May 2009.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться